Cardiovascular benefits of incretins

BMJ (Online)

Volumn 347, Issue 7916, 2013, Pages

  Barnett, Anthony H ^a   O'Hare, Paul ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INCRETIN; INSULIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GLYCEMIC CONTROL; HOSPITAL ADMISSION; HUMAN; HYPOGLYCEMIA; LETTER; MEDICAL RESEARCH; META ANALYSIS (TOPIC); MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC ERROR; TREATMENT OUTCOME; UNITED STATES; WEIGHT GAIN;

ANIMALS; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; PANCREATIC DISEASES;

EID: 84880129040     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f4382     Document Type: Letter

References (9)

1. Cohen D. Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? BMJ 2013;346:f3680. (10 June.)
2. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.
3. Schramm T Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011:32:1900-8.
4. Monami M Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011;27(suppl 3):57-64.
5. Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013;346:f2267.
6. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013;173:534-9.
7. Shyangdan D, Royle P, Clar C, Sharma P, Waugh N. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010,10:20.
8. Butler AE, Cambell-Thompson M, Gurlo T, Dawson D, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-604.
9. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62:2178-80.